Dear Reader,
We have identified several healthtech stocks which are expected to go “Ex-Dividend” starting October, 3, 2022.
If you purchase a stock on its ex-dividend date or after, you will not receive the next dividend payment.
Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend.
So please keep this in mind.
Below is our latest Dividend Report:
Agilent
Symbol: A
Recent A Stock Price: $122.74
Average Analyst Price Target: $151.50 (23.43%)
A Market Cap: $36.63B
Expected Ex-Dividend Date for A stock: Oct 03 2022
Expected Payment Date for A stock: Oct 26 2022
Expected Dividend & Yield for A stock: 0.67%
Recent Analyst Action: Dan Leonard, analyst at Credit Suisse, reiterates coverage on Agilent (A) stock in the Healthcare sector with a Buy rating and a price target of $ 165 (1 month ago).
TipRanks.com also reports that Agilent stock currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $151.50 . The target pricing ranges from a high forecast of $165.00 down to a low forecast of $135.00. Agilent (A)’s last closing stock price was $122.74 which would put the average price target at 23.43% upside.Here are 3rd party ratings for A stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 20% (200 out of 251)
--------------------------------------------------------------------------
Quest Diagnostics
Symbol: DGX
Recent DGX Stock Price: $124.62
Average Analyst Price Target: $147.11 (18.05%)
DGX Market Cap: $14.60B
Expected Ex-Dividend Date for DGX stock: Oct 03 2022
Expected Payment Date for DGX stock: Oct 19 2022
Expected Dividend & Yield for DGX stock: 2.08%
Recent Analyst Action: Erin Wright, analyst at Morgan Stanley, reiterates coverage on Quest Diagnostics (DGX) stock in the Healthcare sector with a Hold rating and a price target of $ 142 (1 month ago).
TipRanks.com also reports that Quest Diagnostics stock currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $147.11 . The target pricing ranges from a high forecast of $165.00 down to a low forecast of $129.00. Quest Diagnostics (DGX)’s last closing stock price was $124.62 which would put the average price target at 18.05% upside.Here are 3rd party ratings for DGX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 14% (217 out of 251)
--------------------------------------------------------------------------
And there you have it...
Keep in mind, if you purchase a stock on its ex-dividend date or after, you will not receive the next dividend payment.
Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend.
If you have questions about specific dividends, you should consult with your financial advisor or visit Investor.gov for more information.
Sincerely,
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
